百奥赛图-B2025 中期报告

百奧賽圖北京醫藥科技股份有限公司Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (A joint stock company incorporated in the People’s Republic of China with limited liability)（於中華人民共和國註冊成立的股份有限公司） Stock code股份代號：2315 CONTENTS 2Corporate Information6Financial Summary7Management Discussion and Analysis50Corporate Governance and Other Information75Review Report77Consolidated Statements of Profit or Loss and OtherComprehensive Income79Consolidated Statements of Financial Position81Consolidated Statements of Changes in Equity82Condensed Consolidated Cash Flow Statements83Notes to the Unaudited Interim Financial Report103Definition Corporate Information CHINESE NAME () ENGLISH NAME BiocytogenPharmaceuticals(Beijing)Co., Ltd.* 02315 STOCK CODE02315 LEGAL REPRESENTATIVEDr. Shen Yuelei CHAIRMAN OF THE BOARDDr. Shen Yuelei HEADOFFICE AND PRINCIPLE PLACE OFBUSINESS IN CHINA 12 12 Baoshen South StreetDaxing Bio-Medicine Industry ParkDaxing District, BeijingPRC REGISTERED OFFICE 12 12 Baoshen South StreetDaxing Bio-Medicine Industry ParkDaxing District, BeijingPRC PRINCIPALPLACE OF BUSINESS IN HONGKONG 24840 40th Floor, Dah Sing Financial CenterNo. 248 Queen’s Road EastWanchaiHong Kong * *For identification purposes only Corporate Information BOARD OF DIRECTORS Executive Directors Dr. Shen Yuelei(Chairman, Chief Executive Officer and General Manager)Dr. Ni JianDr. Zhang Haichao(Senior Operation Director of Animal Center) Non-executive Directors Mr. Wei YiliangDr. Zhou KexiangMs. Zhang Leidi Independent Non-executive Directors Mr. Hua FengmaoDr. Yu ChangyuanMs. Liang Xiaoyan SUPERVISORS Ms. Li YanMs. Sun ChunliDr. Yao Jiawei AUDIT COMMITTEE Ms. Liang Xiaoyan(Chairlady)Mr. Hua FengmaoDr. Yu ChangyuanMr. Wei Yiliang REMUNERATION AND EVALUATION COMMITTEE Mr. Hua Fengmao(Chairman)Ms. Liang XiaoyanDr. Yu ChangyuanDr. Ni Jian Corporate Information NOMINATION COMMITTEE Dr. Yu Changyuan(Chairman)Mr. Hua FengmaoMs. Liang XiaoyanDr. Shen Yuelei STRATEGY DEVELOPMENT COMMITTEE Dr. Shen Yuelei(Chairman)Dr. Zhou KexiangMr. Wei YiliangMs. Zhang Leidi JOINT COMPANY SECRETARIES Mr. Wang YongliangMs. Au Wai Ching(fellow member of The Hong Kong CharteredGovernance Institute and The Chartered Governance Institute inthe United Kingdom) AUTHORIZED REPRESENTATIVES Dr. Shen YueleiMs. Au Wai Ching AUDITOR 108 Public Interest Entity Auditor registered in accordance with theAccounting and Financial Reporting Council Ordinance8th Floor, Prince’s Building10 Chater RoadCentral, Hong Kong Corporate Information H H SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong LEGAL ADVISERS TO HONG KONG LAW 3A10 Davis Polk & Wardwell10th Floor, The Hong Kong Club Building3A Chater Road, Hong Kong PRINCIPAL BANKS 2 China Construction Bank, Beijing Economic and TechnologicalDevelopment Zone Sub-branchNo. 2, Jingyuan North StreetDaxing DistrictBeijing, PRC 881 China Merchants Bank, Beijing Yizhuang Sub-branch1/F, Building 8, Libao PlazaNo. 8 Ronghua Middle RoadDaxing DistrictBeijing, PRC COMPANY WEBSITE http://www.biocytogen.com.cn http://www.biocytogen.com.cn CONTACT INFORMATION FOR INVESTORS Tel.: 010-56967601Fax: 010-56967666-8067Email: ir@bbctg.com.cn Tel.: 010-56967601Fax: 010-56967666-8067Email: ir@bbctg.com.cn Financial Summary I. I.BUSINESS REVIEW Overview 2 0 0 9RenMice®1,0001,000,000BioMiceTM Founded in 2009, we are a global biotechnology company thatdrives the research and development of novel antibody-baseddrugsand pre-clinical research services.Founded on geneeditingtechnology,we leverage genetically engineeredproprietaryRenMice®platforms for fully human antibodydiscovery, and have established a Project Integrum technologyplatform, for which an off-the-shelf library of more than 1,000,000fully human antibody sequences against over 1,000 targets hasbeen built for worldwide collaboration. Biocytogen also reachedseveralantibody molecules in clinical stage out-licensing orcollaboration, and currently provides a few thousand off-the-shelfanimaland cell models under the company’s sub-brand,BioMiceTM, along with pre-clinical pharmacology and gene-editingservices for clients worldwide. We are headquartered in Beijingandhave branches in China(Haimen in Jiangsu,Shanghai),USA(Boston,San Francisco and San Diego),and Germany(Heidelberg). 20252025 Since 2025, under the influence of various factors, the externalenvironmenthas undergone significant changes,with theoverallmacroeconomic environment showing a steady andpositivetrend.In particular,the biopharmaceutical industry,after experiencing a period of downturn, has entered a stage ofrecovery. The Company has always adhered to its strategic goalof “driving new drug development with innovative technologies”,maintaining a relatively high level of R&D investment, targetingthe global market, and providing globally competitive productsandservices to domestic and overseas biopharmaceuticalenterprises.Benefitin